Pilot phase 2 trial of 4 months of maintenance pegylated liposomal doxorubicin in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy

Gynecologic and Obstetric Investigation

Volumn 63, Issue 1, 2007, Pages 1-6

  DiSilvestro, Paul A ^a,c   Fisher, Margaret ^a   Pearl, Michael L ^a   Buhl, Ann ^a   Chalas, Eva ^a   Valea, Fidel A ^b  

^a Long Island Gynecologic Oncologists   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Consolidation; Liposomal doxorubicin; Ovarian cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEARING DISORDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LEUKOCYTE; LIVER TOXICITY; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAINTENANCE THERAPY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PILOT PROJECTS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33845951215     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094361     Document Type: Article

References (16)

1. McGuire WP, Hoskins WJ, Brady MF, Ducera PR, Partridge EE, Look KY, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2000;18:106-115.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3194-3200.
4. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the southwest oncology group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-717.
5. Alberts DS, Liu PH, Hannigan EV, O'Toole R, Williams SD, Young JA, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
6. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts DS, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol 2003;21:2460-2465.
7. Muggia F, Kim E, Gaiotti D, et al: Safety of prolonged doxil administration in recurrent gynecologic cancers. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(suppl):5055.
8. DePlacido S, Scambia G, DiVagno G, Nagliere E, Lombardi AV, Biamonte R, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. J Clin Onc 2004;22:2635-2642.
9. Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, et al: Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002;20:694-698.
10. Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, et al: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group Trial (SWOG-9326). Gynecol Oncol 2001;82:317-322.
11. McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R: Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol 2004;95:157-164.
12. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitiors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-86.
13. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Onc 2004;22:3120-3125.
14. O'Brian ME, Wigler N, Inbar RR, Grischke E, Santoro A, Carane R, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
15. Gordon AN, Tonda M, Sun S, Rackoff W, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
16. Hussein MA, Wood L, Hsi E, Skralovic G, Karam M, Elson P, et al: A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002;95:2160-2168.